Рет қаралды 214
Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 (NCT03434379), a study investigating atezolizumab and bevacizumab vs sorafenib for unresectable hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).